iAtoday

At the Congrès Collectif 2026, held at the Palais des congrès in Montreal on February 27, Frédéric Leblanc, Strategic Lead, Products and Drug Programs, took part in a panel that addressed the emerging issues transforming group insurance, particularly in the area of drugs and cost management.

The panel discussed the following topics:

• The restructuring of group sizes planned by the Quebec Drug Insurance Pooling Corporation in 2027
• The challenges of high-cost drugs and treatments for rare diseases
• The impact of generic and biosimilar drugs on cost control
• Prevention and deprescribing initiatives aimed at more appropriate medication use

Recognized for his deep insight into pharmaceutical dynamics and drug insurance plans, Frédéric shone a practical light on how therapies are evolving, the financial pressures that accompany them and the strategies that foster innovation and treatment options while protecting the long-term health of group insurance plans.

His contribution highlighted our rigorous and proactive approach, built on analysis, collaboration and clinical expertise to better support you and the clients you serve.

Frédéric Leblanc’s participation in this panel underscores our commitment to be at the forefront of emerging trends in group insurance and to actively contribute to the conversations that are shaping the future of our industry.

Unabled to attend the event? Or want to watch the discussions again? A recording of the Congrès Collectif 2026 is available online (in French only).

Want to find out more about our sustainable healthcare initiatives and PharmAssist^®, our one-stop shop for drug management? Contact your iA Financial Group Account Executive.

We will be sending out a communiqué to group insurance plan administrators on March 23 (French version).